


Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

652 patients

- 346 myelodysplastic syndromes
- 53 myelodysplastic/myeloproliferative neoplasms
- 253 controls

Flow cytometry staining

CD45	CD7
CD34	CD56
CD10	CD5
CD19	



Assesment of Ogata's score
Specificity of Ogata score 89%

